Lido Advisors, LLC Gilead Sciences, Inc. Transaction History

Lido Advisors, LLC

$21.7 Billion
Q4 2024

A detailed history of Lido Advisors, LLC transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Lido Advisors, LLC holds 63,754 shares of GILD stock, worth $7.01 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

63,754

Previous 59,074 7.92%

Holding current value

$7.01 Million

Previous $4.95 Million 18.93%

% of portfolio

0.03%

Previous 0.02%

33 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$83.95 - $97.9 $392,886 - $458,172	4,680 Added 7.92%	63,754 $5.89 Million
Q3 2024 Nov 14, 2024	BUY	$66.59 - $83.99 $62,860 - $79,286	944 Added 1.62%	59,074 $4.95 Million
Q2 2024 Aug 14, 2024	SELL	$63.15 - $72.88 $106,407 - $122,802	-1,685 Reduced 2.82%	58,130 $3.99 Million
Q1 2024 May 15, 2024	BUY	$71.58 - $87.29 $523,035 - $637,828	7,307 Added 13.92%	59,815 $4.38 Million
Q4 2023 Feb 14, 2024	BUY	$73.27 - $83.09 $60,301 - $68,383	823 Added 1.59%	52,508 $4.25 Million
Q3 2023 Nov 14, 2023	BUY	$73.94 - $80.67 $516,470 - $563,479	6,985 Added 15.63%	51,685 $3.87 Million
Q2 2023 Aug 09, 2023	SELL	$76.01 - $86.7 $2.68 Million - $3.05 Million	-35,205 Reduced 44.06%	44,700 $3.45 Million
Q1 2023 May 15, 2023	SELL	$77.31 - $88.08 $188,945 - $215,267	-2,444 Reduced 2.97%	79,905 $6.63 Million
Q4 2022 Feb 14, 2023	BUY	$62.32 - $89.47 $3.32 Million - $4.77 Million	53,331 Added 183.79%	82,349 $7.07 Million
Q3 2022 Nov 14, 2022	BUY	$59.54 - $68.01 $1.2 Million - $1.37 Million	20,073 Added 224.4%	29,018 $1.79 Million
Q2 2022 Aug 15, 2022	SELL	$57.72 - $65.01 $120,288 - $135,480	-2,084 Reduced 18.9%	8,945 $552,000
Q1 2022 May 17, 2022	BUY	$57.92 - $72.58 $5,792 - $7,258	100 Added 0.91%	11,029 $655,000
Q4 2021 Feb 15, 2022	SELL	$64.88 - $73.64 $3,827 - $4,344	-59 Reduced 0.54%	10,929 $793,000
Q3 2021 Nov 12, 2021	SELL	$67.69 - $73.03 $2.3 Million - $2.48 Million	-33,949 Reduced 75.55%	10,988 $768,000
Q2 2021 Aug 12, 2021	SELL	$63.47 - $69.35 $78,131 - $85,369	-1,231 Reduced 2.67%	44,937 $3.09 Million
Q1 2021 May 13, 2021	BUY	$60.0 - $68.46 $959,640 - $1.09 Million	15,994 Added 53.01%	46,168 $2.98 Million
Q4 2020 Feb 08, 2021	SELL	$56.65 - $64.55 $3.02 Million - $3.44 Million	-53,366 Reduced 63.88%	30,174 $1.76 Million
Q3 2020 Nov 12, 2020	BUY	$62.1 - $78.08 $633,357 - $796,337	10,199 Added 13.91%	83,540 $5.28 Million
Q2 2020 Aug 12, 2020	BUY	$72.34 - $84.0 $3.5 Million - $4.06 Million	48,363 Added 193.62%	73,341 $5.64 Million
Q1 2020 May 13, 2020	SELL	$62.63 - $80.22 $272,315 - $348,796	-4,348 Reduced 14.83%	24,978 $1.87 Million
Q4 2019 Feb 07, 2020	BUY	$61.62 - $67.78 $1.5 Million - $1.65 Million	24,313 Added 485.0%	29,326 $1.91 Million
Q3 2019 Nov 12, 2019	SELL	$62.51 - $69.0 $226,473 - $249,987	-3,623 Reduced 41.95%	5,013 $318,000
Q2 2019 Aug 14, 2019	SELL	$61.87 - $69.38 $27,099 - $30,388	-438 Reduced 4.83%	8,636 $583,000
Q1 2019 May 10, 2019	BUY	$62.53 - $70.05 $437 - $490	7 Added 0.08%	9,074 $589,000
Q4 2018 Feb 14, 2019	BUY	$60.54 - $79.0 $190,640 - $248,771	3,149 Added 53.21%	9,067 $567,000
Q3 2018 Nov 14, 2018	BUY	$71.28 - $78.92 $39,346 - $43,563	552 Added 10.29%	5,918 $456,000
Q2 2018 Aug 14, 2018	SELL	$64.88 - $75.68 $1,686 - $1,967	-26 Reduced 0.48%	5,366 $380,000
Q1 2018 May 10, 2018	SELL	$72.84 - $88.8 $61,112 - $74,503	-839 Reduced 13.46%	5,392 $406,000
Q4 2017 Feb 15, 2018	SELL	$71.15 - $83.52 $46,389 - $54,455	-652 Reduced 9.47%	6,231 $446,000
Q3 2017 Nov 13, 2017	BUY	$72.11 - $85.47 $496,333 - $588,290	6,883 New	6,883 $515,000
Q3 2016 Sep 21, 2017	SELL	N/A	-2,712 Closed	0 $0
Q2 2016 Sep 18, 2017	SELL	N/A	-2,821 Reduced 50.98%	2,712 $226,000
Q1 2016 Sep 18, 2017	BUY	N/A	5,533	5,533 $508,000

Others Institutions Holding GILD

# of Institutions

2,090

Shares Held

1.02B

Call Options Held

8.73M

Put Options Held

9.63M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $138B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lido Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lido Advisors, LLC with notifications on news.

Account

Lido Advisors, LLC Gilead Sciences, Inc. Transaction History